Nektar Therapeutics (NKTR) Misses Q1 EPS by 7c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq retreat from record highs as yields and oil climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $39.56 -0.88%
Revenue Growth %: -13.0%
Financial Fact:
Income (loss) from operations: -32.9M
Today's EPS Names:
AEHR, VFS, CMTL, More
Revenue Growth %: -13.0%
Financial Fact:
Income (loss) from operations: -32.9M
Today's EPS Names:
AEHR, VFS, CMTL, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.78), $0.07 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $50.57 million versus the consensus estimate of $47.64 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Parabolic reports preliminary Q3 2026 revenue of $4.7 million
- Deutsche Bank's top picks in mining as copper market faces potential squeeze
- RenovoRx enrolls first patient in UVM-sponsored PRISM-TAMP trial
Create E-mail Alert Related Categories
Corporate News, Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
